Ironwood Pharmaceuticals Inc Class A IRWD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
-
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
-
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
-
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
-
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
-
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Trading Information
- Previous Close Price
- $4.67
- Day Range
- $4.37–4.65
- 52-Week Range
- $0.67–5.78
- Bid/Ask
- $4.46 / $4.49
- Shares Outstanding
- 164.61M
- Market Cap
- $735.82M
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 7.69
- Price/Sales
- 2.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 100
- Website
- https://www.ironwoodpharma.com
Valuation
|
Metric
|
IRWD
|
|---|---|
Price/Earnings (Normalized) | 7.69 |
Price/Book Value | — |
Price/Sales | 2.17 |
Price/Cash Flow | 4.34 |
Price/Earnings
IRWD
Financial Strength
|
Metric
|
IRWD
|
|---|---|
Quick Ratio | 1.38 |
Current Ratio | 1.41 |
Interest Coverage | 5.95 |
Quick Ratio
IRWD
Profitability
|
Metric
|
IRWD
|
|---|---|
Return on Assets (Normalized) | 30.52% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 43.13% |
Return on Assets
IRWD
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|xZfc$?p | LOCK|mG<J# | $69B | |||
| Haleon PLC ADR
HLN
| LOCK|Ry<Ssy | LOCK|KQ | $43B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|@$#tYZKc | LOCK|pK#< | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|y!FD!<%r | LOCK|B#K | $32B | |||
| Viatris Inc
VTRS
| LOCK|$z<X%b | LOCK|^NR | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|^!% | LOCK|#M | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|#jDSj@ | LOCK|$D | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|R^RM%WK | LOCK|Pk | $8B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|$%KyW! | LOCK|N<SH | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|&PPRM@ | LOCK|%L | $1B |
United States